ProBioGen and Spica Therapeutics, a biotechnology company advancing pathogenic macrophage subset-targeted immunotherapies, have entered a new collaboration in which ProBioGen will perform cell line development for ST101, Spica’s first clinical development candidate anti-CD163 depleting antibody for oncology. ST101 is a first-in-class monoclonal antibody designed to selectively deplete immunosuppressive CD163+ tumor-associated macrophages (TAMs). Spica has integrated ProBioGen’s proprietary Gl...